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Background: Antiretroviral pre-exposure prophylaxis (PrEP) is
a novel HIV prevention strategy for which adherence is a known
determinant of efﬁcacy. Blood concentrations of PrEP medications
are one objective marker of adherence.
Methods: In a placebo-controlled PrEP efﬁcacy trial of tenofovir
disoproxil fumarate (TDF) and TDF with emtricitabine (FTC/TDF)
among 4747 African women and men with an HIV-infected partner,
we measured plasma tenofovir concentrations from participants in
the active PrEP arms: 29 HIV seroconverters (cases) and 196
randomly selected controls who remained uninfected.
Results: Among controls, 71% of visits had tenofovir concen-
trations .40 ng/mL, consistent with steady-state daily dosing, com-
pared with 21% of cases at the visit HIV was ﬁrst detected. Pill count
data indicated that 96% of controls and 66% of cases had .80%
adherence for these same visits. The estimated protective effect of
PrEP against HIV, based on concentrations .40 ng/mL, was 88%
(95% conﬁdence interval: 60 to 96, P , 0.001) for individuals
receiving TDF and 91% (95% conﬁdence interval: 47 to 98, P =
0.008) for individuals receiving FTC/TDF. Controls had consistent
patterns of PrEP concentrations during follow-up; among the 81%
with concentrations .40 ng/mL at month 1, 75% maintained this
concentration at month 12. Only 5 of 29 seroconverters seemed to be
consistently adherent to PrEP. Tenofovir concentrations .40 ng/mL
were associated with older age and shorter time on study; concen-
trations #40 ng/mL occurred more commonly when participants
reported no sex with their HIV-infected partner.
Conclusions: Plasma concentrations of tenofovir consistent with
daily dosing were highly predictive of protection from HIV
acquisition. Most of those who took PrEP seemed to have high
and consistent adherence.
Key Words: Africa, HIV prevention, pre-exposure prophylaxis,
serodiscordant couples, adherence, drug concentrations
(J Acquir Immune Deﬁc Syndr 2014;66:340–348)
INTRODUCTION
Antiretroviral pre-exposure prophylaxis (PrEP) with
once-daily tenofovir disoproxil fumarate (TDF) or combina-
tion emtricitabine (FTC/TDF) is an effective HIV prevention
strategy for HIV-uninfected persons at high risk of infection.
Four randomized placebo-controlled efﬁcacy trials have
demonstrated the efﬁcacy of daily oral PrEP for HIV
prevention among diverse populations, including men who
have sex with men (MSM) from multiple countries, young
African heterosexuals, African heterosexual HIV serodiscord-
ant couples, and injection drug users in Thailand.
1–4 PrEP
clinical trials have also pointed to the critical need for high
adherence to achieve HIV protection, with the degree of HIV
protection across clinical trials (from 44% to 75%) strongly
related to PrEP adherence in the trial population. Two
efﬁcacy trials of oral PrEP in young African women did
not demonstrate HIV protection, as a result of very low
adherence.
5,6
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African HIV serodiscordant couples, the degree of HIV
protection in the randomized comparison was 67% for TDF
and 75% for FTC/TDF.
4 By several indicators, including high
visit-to-visit clinic attendance, clinic- and home-based pill
counts of unused study product, medication electronic mon-
itoring, and plasma drug levels, adherence to PrEP was high
in the study population.
7 In this study, we used the detection
of tenofovir in plasma to estimate HIV protection efﬁcacy by
quantitative drug concentrations in plasma and to explore
adherence sampled over time and its association with partic-
ipant characteristics. To assess accuracy of pill count data to
monitor adherence, detectable tenofovir in plasma was com-
pared with clinic-based pill count data.
METHODS
Population
The Partners PrEP Study was a phase 3, randomized,
double-blind, placebo-controlled, 3-arm clinical trial of daily
oral TDF and FTC/TDF PrEP among HIV-uninfected members
of HIV serodiscordant couples. Beginning in 2008, 4747
couples were randomized and followed at 9 clinical research
sites in Kenya and Uganda. The design, procedures, and
outcomes of the trial are described elsewhere.
4 Brieﬂy, HIV-
uninfected partners were randomly assigned to once-daily TDF,
FTC/TDF, or matching placebo and followed monthly for
safety assessments and HIV seroconversion for up to 36
months. Plasma was stored at months 1, 3, and quarterly there-
after, plus at any visit where a participant tested positive for
HIV. HIV-infected partners were not eligible for antiretroviral
therapy under national guidelines at the time of enrollment but
were monitored and actively referred for antiretroviral treatment
initiation if they became eligible during follow-up. All couples
received a package of HIV prevention services, including risk-
reduction counseling, couples counseling, and condoms. In July
2011, the trial’s independent Data and Safety Monitoring Board
recommended public report of the results and discontinuation of
the trial’s placebo arm because of the demonstration of 67%
efﬁcacy for HIV protection with TDF and 75% efﬁcacy with
FTC/TDF. The trial was subsequently continued with all par-
ticipants receiving active TDF or FTC/TDF PrEP. The present
analysis includes data through July 2011.
Laboratory Procedures
HIV seroconversions were detected by rapid HIV tests
conducted in duplicate at the study sites, with conﬁrmatory
testing by HIV Western blot. In addition, after seroconversion
was conﬁrmed, archived plasma samples from visits before
seroconversion were tested for HIV RNA by polymerase
chain reaction to more precisely determine the timing of HIV
acquisition.
Plasma tenofovir concentrations were determined in
selected archived plasma samples by previously described
ultra-performance liquid chromatography-mass spectrometry
assay methods.
8,9 Tenofovir assays meet the FDA bioanalysis
guidance values of within 615% for precision and accuracy.
Thawed aliquots of plasma with 13C5-TFV internal standard were
protein precipitated with methanol. Samples underwent chro-
matographic separation using gradient elution with a Zorbax
Eclipse XDB-C18 column, with positive electrospray ionization,
and detection through multiple reaction monitoring using an LC-
MS/MS system (Waters Acquity UPLC and Agilent 1100
HPLC, API4000 mass spectrometer; Applied Biosystem). Cali-
bration standards for assay ranged from 0.31 to 1280 ng/mL.
Case–Cohort Study of Tenofovir Plasma
Drug Concentrations
A case–cohort design in the active PrEP arms of the
trial (ie, TDF and FTC/TDF arms) was used to assess the
association between HIV infection and plasma concentrations
of tenofovir. A cohort of 200 participants was randomly
selected (100 from the TDF arm and 100 from the FTC/
TDF arm), with all 30 HIV seroconverters from the PrEP
arms comprising the cases (17 from the TDF arm and 13 from
the FTC/TDF arm). Two participants from the cohort were
lost to follow-up and 2 seroconverted to HIV, leaving 196
HIV-uninfected participants as the control population (100
TDF and 96 FTC/TDF). For these controls, 945 plasma sam-
ples were tested from available study visits 1, 3, 6, 12, 18, 24,
30, and 36 months after enrollment. Of the 30 seroconverters,
1 did not have stored samples after enrollment; for the re-
maining 29, 85 samples were tested from the same visit
schedule as controls before HIV infection plus the visit at
which HIV infection was ﬁrst detected (either by HIV sero-
conversion or in a preseroconversion sample by HIV RNA
polymerase chain reaction; for 14 of the 29 seroconverters,
HIV RNA was detected in an archived plasma sample before
seroconversion). In results previously reported from this clin-
ical trial, plasma tenofovir concentrations from the time of
seroconversion were analyzed, without consideration of HIV
RNA detection before seroconversion.
10
Statistical Analysis
Three threshold concentrations of plasma tenofovir
levels were used to categorize participant’s adherence: (1)
.0.31 ng/mL (the assay limit of quantitation referred to here-
after as “detectable”), which is consistent with dosing within
the last week; (2) .10 ng/mL, consistent with dosing in the
last 2–3 days; and (3) .40 ng/mL, the lower 95% conﬁdence
interval (CI) 24 hours after dose for directly observed daily
dosing at steady state.
11–14 The temporal dosing references of
these concentration thresholds are based on population-based
values and will vary for a given individual because of phar-
macokinetic (PK) differences within a population. Concentra-
tions .40 ng/mL are consistently achieved with daily dosing
but are also likely in persons who took a single dose in the
last 24 hours. In PrEP trials reported to date, either the 0.31
ng/mL or the 10 ng/mL threshold has been used to deﬁne
detectable tenofovir in plasma.
1,6
The case–cohort analysis was performed using tenofo-
vir concentrations in all participants irrespective of drug holds
in the previous interval (eg, for pregnancy or evaluation of
adverse events). Design calibration methods were used to
compute hazard ratios from a Cox proportional hazards model
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tion from covariates in all active arm participants was used to
predict plasma drug concentrations from pill count coverage,
age, and occupation. These models, through inﬂuence func-
tions, were used to adjust the sampling for imbalances in the
cohort selected for plasma testing.
15,16 E s t i m a t e so fH I Vp r o -
tective effect could be affected by potential confounding with
factors associated with adherence and HIV risk, therefore the
analysis was conducted both with drug levels as the only co-
variate and also adjusted for covariates found to correlate with
adherence (gender, age, and any sex with study partner
7). Anal-
ysis was conducted in the R survey package Version 3.0.1.
17
Drug dispensing records and counts of the returned pills
were used to calculate pill count “coverage,” deﬁned as the
percentage of days in the previous month pills were available
and taken i.e. (pills dispensed–pills returned)/(elapsed days
since last visit). Pill count coverage was zero where drug
was not dispensed (eg, for protocol-speciﬁed holds such as
pregnancy or adverse events) and incorporated imperfect cov-
erage when there were insufﬁcient pills for the elapsed days
as a result of missed or late visits. When contrasting non-
adherence measured by plasma drug concentrations with pill
count coverage, we compared undetectable tenofovir concen-
trations and pill count coverage .80%, noting that pill count
.80% corresponds to taking pills at least 22 of the previous
28 days and a pill taken in the last 6 days would result in
detectable drug since tenofovir typically remains detectable
for 14 days.
13 Analysis of correlates of steady-state daily
adherence (.40 ng/mL) in controls included time on study,
sociodemographic characteristics (gender, age, education,
occupation, and study arm), visit-level risk behaviors (any
sex and any unprotected sex with study partner in the previous
month, any outside partner, or polygamous marriage), and
clinical characteristics of the HIV-infected partner (baseline
HIV plasma viral load, baseline and follow-up CD4 counts,
and initiation of antiretroviral therapy). Correlates of adher-
ence were assessed using logistic regression with generalized
estimating equation methods to account for repeated measures
across visits, assuming an exchangeable covariance structure.
Visits with participants on study drug hold were excluded.
Ethics
The study protocol was approved by the Ethics Review
Committees at the University of Washington and each study site.
The trial is registered with ClinicalTrials.gov (NCT00557245).
All participants provided written informed consent.
RESULTS
Participant Characteristics
Demographic, clinical, and behavioral characteristics of
cases and controls were similar to the entire active arm cohort
in the trial (see Table, Supplemental Digital Content 1,
http://links.lww.com/QAI/A519, which demonstrates charac-
teristics of the study population), with the exception that CD4
counts in HIV-infected partners of seroconverters were lower
by 114 cells per cubic millimeter compared with nonsero-
converters (P = 0.002). The median number of samples tested
in controls was 5 [interquartile range (IQR): 4–6] and in cases
was 4 (IQR: 3–5), representing 96% and 90% of all possible
visits, respectively.
Detection of Tenofovir in Plasma
Drug concentrations .40 ng/mL, consistent with
steady-state dosing, were detected in 71% of samples from
controls (72% TDF and 70% FTC/TDF; Table 1); for the 19
cases, concentrations .40 ng/mL were detected in 48% of
samples, in visits before HIV infection (49% TDF and 47%
FTC/TDF). At the ﬁrst visit when HIV infection was detected,
only 6 of 31 (21%) seroconverters had concentrations .40
ng/mL, although 9 had detectable tenofovir (7 on TDF, with 3
TABLE 1. Plasma Tenofovir Concentrations, Missed Visits, and Pill Count Coverage by Case–Control Status
TDF Cases: HIV Seroconverters
(N = 17)
TDF Controls: HIV
Uninfected (N = 96)
FTC/TDF Cases: HIV
Seroconverters (N = 12)
FTC/TDF Controls: HIV
Uninfected (N = 100)
All Visits Before
Infection
First HIV-
Infected Visit All Visits
All Visits Before
Infection
First HIV-
Infected Visit All Visits
Samples tested for
drug level (N)
51 17 455 34 12 490
Detectable tenofovir
drug*
.0.3 ng/mL 29 (57%) 7 (41%) 378 (83%) 22 (65%) 2 (17%) 395 (80%)
.10 ng/mL 29 (57%) 7 (41%) 361 (79%) 19 (56%) 2 (17%) 369 (76%)
.40 ng/mL 25 (50%) 4 (24%) 328 (72%) 16 (47%) 2 (17%) 342 (70%)
No tenofovir detected 22 (43%) 10 (59%) 77 (17%) 12 (35%) 10 (83%) 96 (20%)
On protocol drug
hold
3 3 14 0 0 6
Missed previous
visit†
01 2 04 2
Pill count coverage
.80%
46 (90%) 12 (71%) 431 (95%) 31 (91%) 7 (58%) 474 (97%)
*Rows are not mutually exclusive.
†Visits were scheduled every 28 days with an allowable window of 614 days. A visit is considered missed if more than 28 + 14 = 42 days have elapsed.
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both .40 ng/mL). Samples from controls and cases had sim-
ilar, and low, rates of study drug interruptions because of preg-
nancy or clinical safety holds (20/945 control visits = 2.1% and
3/85 case visits = 3.5%, P = 0.11). Three of the 29 seroconvert-
ers, all on the TDF arm, who were on a drug hold at the time
HIV infection was ﬁrst detected (2 for pregnancy and 1 for
a safety-related drug hold). Pill count data show a high pro-
portion of visits with high adherence in controls (96%) and in
cases, prior to HIV infection (91%), but substantially lower in
cases’ visits immediately before HIV acquisition (66%). In all
groups, tenofovir concentrations indicate substantially lower
adherence than pill count data.
Quantitative concentrations of tenofovir, when detected,
did not differ between controls and cases before infection
[median: 81 ng/mL (IQR: 57–116) for controls versus median:
78 ng/mL (IQR: 52–118) for cases; (P = 0.6)]. In 9 cases with
detectable tenofovir at the visit when HIV infection was de-
tected, median tenofovir concentration was 49 ng/mL (IQR:
26–82), somewhat lower than controls (P = 0.08). Among
controls, median tenofovir concentrations were similar in
men and women (men: 83, IQR: 57–120; women: 78, IQR:
57–111; P =0 . 5 ) .
Participants who did not have detectable drug
(,0.31 ng/mL) at their month 1 visit represented 11% of
controls and consistently had low concentrations of drug
(Fig. 1A), demonstrating a pattern of early nonadherence or
noninitiation. Participants with detectable but low plasma con-
centrations (#40 ng/mL) at month 1 (8%) subsequently show
ﬂuctuating tenofovir concentrations (Fig. 1B). Those with
FIGURE 1. Change in plasma level detected by visit in control and cases. Levels of tenofovir detected are grouped by unde-
tectable (,0.31), detectable but less than daily dosing (0.31, 40.0) and consistent with steady-state dosing (.40) ng/mL in
plasma. Figures 1a, 1b and 1c show individual patterns in control participants grouped by the levels of tenofovir quantiﬁed at the
month 1 visit (green #0.31, orange = 0.31, 40.0, blue $40) ; each participant is represented by one line and lines terminate at
each participant’s last visit. Figure 1d shows the plasma levels of the 29 seroconverters; the ﬁnal value shown corresponds to the
tenofovir plasma level at ﬁrst visit at which HIV infection was detected. Off drug means on clinical drug hold as a result of
pregnancy, AE or other reason.
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largely consistent adherers; 100 of 133 (75%) of these month
1 adherers had concentrations .40 ng/mL at month 12 and
66 of 92 (72%) at month 18 (Fig. 1C). When tenofovir con-
centrations were undetectable in this group [eg, 20/133 (15%)
at month 12 and 16/92 (17%) at month 18], only a minority
(6 of 36, or 17%) were attributable to drug holds because
of pregnancy or clinical safety events. In the seroconverters,
where infection was detected at the last visit shown in
Figure 1D, 5 of the 29 (17%) seroconverters had concen-
trations consistently .40 ng/mL throughout study follow-
up; of these 5, 3 were women on the TDF arm, 1 a man, and
1aw o m a no nt h eF T C / T D Fa r m .
Plasma Tenofovir Concentrations and
HIV Protection
Plasma tenofovir concentrations at all 3 thresholds
(.0.31, .10, and .40 ng/mL) were highly predictive of pro-
tection from HIV infection (Table 2). Plasma concentration of
tenofovir .40 ng/mL was associated with HIV protection of
88% in the TDF arm (95% CI: 60% to 96%, P , 0.001) and
91% in the FTC/TDF arm (95% CI: 47% to 98%, P = 0.008),
concentration of tenofovir .10 ng/mL with 80% HIV protec-
tion in the TDF arm (95% CI: 44% to 93%, P =0 . 0 0 2 )a n d
92% in the FTC/TDF arm (95% CI: 58% to 99%, P = 0.003),
and tenofovir .0.3 ng/mL with 84% protection in the TDF arm
(95% CI: 54% to 94%, P = 0.001) and 92% in the FTC/TDF
arm (95% CI: 67% to 99%, P = 0.001). Separate gender sub-
group analysis of TDF and FTC/TDF shows similar protection
for men and women, with the exception of women in the TDF
arm at the lower tenofovir thresholds, where association with
protection at both the .0.3 and .10 ng/mL concentration were
low, although with wide conﬁdence limits (Table 2).
Predictors of High Plasma
Tenofovir Concentrations
In multivariate analysis, correlates of tenofovir .40
ng/mL, consistent with daily adherence, were older age [adjusted
TABLE 2. HIV Risk Reduction for 3 Threshold Concentrations of Tenofovir in Plasma
Cases: Before
HIV Infection
Cases: First HIV-
Infected Visit Controls
Risk Reduction†
(95% CI), % P
Adjusted* Risk
Reduction†
(95% CI), % Adjusted P
Tenofovir .0.3 ng/mL
Overall
TDF 29/51 (57%) 7/17 (41%) 378/455 (83%) 84% (54 to 94) 0.001 82% (46 to 94) 0.002
FTC/TDF 22/34 (64%) 2/12 (17%) 394/490 (80%) 92% (67 to 99) 0.001 93% (60 to 99) 0.003
Men
TDF 10/29 (35%) 1/9 (11%) 240/283 (85%) 97% (75 to 100) 0.001 98% (77 to 100) 0.001
FTC/TDF 8/12 (67%) 1/4 (25%) 259/315 (82%) 89% (219 to 99) 0.07 ——
Women
TDF 19/22 (86%) 6/8 (75%) 138/172 (80%) 21% (2274 to 83) 0.77 34% (2287 to 89) 0.65
FTC/TDF 14/22 (64%) 1/8 (13%) 135/175 (77%) 94% (41 to 99) 0.02 96% (35 to 100) 0.02
Tenofovir .10 ng/mL
Overall
TDF 29/51 (57%) 7/17 (41%) 361/455 (79%) 80% (44 to 93) 0.002 77% (32 to 92) 0.008
FTC/TDF 19/34 (56%) 2/12 (17%) 369/490 (76%) 92% (58 to 99) 0.003 91% (46 to 99) 0.008
Men
TDF 10/29 (35%) 1/9 (11%) 226/283 (80%) 97% (70 to 100) 0.002 97% (73 to 100) 0.002
FTC/TDF 7/12 (58%) 1/4 (25%) 243/315 (77%) 85% (265 to 99) 0.12 ——
Women
TDF 19/22 (86%) 6/8 (75%) 135/172 (79%) 12% (2427 to 82) 0.88 16% (2273 to 81) 0.82
FTC/TDF 12/22 (54%) 1/8 (13%) 126/175 (72%) 93% (25 to 99) 0.03 94% (6 to 100) 0.04
Tenofovir .40 ng/mL
Overall
TDF 25/51 (49%) 4/17 (24%) 328/455 (72%) 88% (60 to 96) ,0.001 87% (59 to 96) ,0.001
FTC/TDF 16/34 (47%) 2/12 (17%) 342/490 (70%) 91% (47 to 98) 0.008 88% (31 to 98) 0.018
Men
TDF 8/29 (28%) 1/9 (11%) 208/283 (74%) 95% (58 to 99) 0.006 95% (60 to 99) 0.005
FTC/TDF 6/12 (50%) 1/4 (25%) 223/315 (71%) 80% (2128 to 98) 0.19 ——
Women
TDF 17/22 (77%) 3/8 (38%) 120/172 (70%) 76% (29 to 95) 0.06 85% (290 to 99) 0.14
FTC/TDF 10/22 (45%) 1/8 (13%) 119/175 (68%) 92% (19 to 99) 0.03 94% (217 to 100) 0.07
*Adjusted for gender, any sex with study partner in last month, and age #25. Adjusted model not estimable in male FTC/TDF subgroup.
†% Risk reduction = (1 2 hazard ratio) · 100.
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10 years, P = 0.04] and couples whose primary income was from
farming (aOR: 1.7, 95% CI: 1.2 to 2.6, P = 0.008). Not having
sex compared with reporting unprotected sex with the HIV-
infected study partner, aOR: 0.5, 95% CI: 0.3 to 0.9, P =0 . 0 2 )
and longer time on study (aOR: 0.83, 95% CI: 0.76 to 0.92,
for each additional 6 months on study drug, P , 0.001) were
associated with lower likelihood of having tenofovir detected
at .40 ng/mL (Table 3).
PrEP Adherence: Pill Count Coverage
Compared With Plasma Concentrations
The majority of control samples had tenofovir plasma
concentrations consistent with pill count coverage in the
previous month (Fig. 2); in visits with high pill count cover-
age (80%–103%), 592 of 779 (76%) had tenofovir plasma
concentrations .40 ng/mL; with low pill count coverage
(,80%), only 7 of 42 (17%) had tenofovir concentrations
.40 ng/mL. For pill count coverage above 103% (coverage
.100% occurs when fewer pills are returned than expected),
tenofovir concentrations .40 ng/mL occurred in only 65 of
115 (57%). Notably, 141 of 936 (15%) had high pill count
coverage (.80%) but undetectable tenofovir in plasma, indi-
cating over-estimation of adherence by pill counts.
DISCUSSION
Clinical trials in 4 different populations have provided
strong evidence that daily oral PrEP is efﬁcacious in
preventing HIV infection.
1–4 In each of these trials, analysis
of blood tenofovir concentrations provided strong supporting
objective evidence that PrEP taking behaviors, indicated by
detectable tenofovir, conferred high levels of HIV protection.
Our analysis of tenofovir concentrations at the ﬁrst
HIV-infected visit in the Partners PrEP Study showed HIV
protection of 88% for TDF and 91% for FTC/TDF for par-
ticipants with high adherence at steady-state levels (plasma
tenofovir .40 ng/mL). This high level of protection was
attributed to consistently high-drug concentrations from the
TABLE 3. Univariable and Multivariable Regressions of Factors Correlating With Tenofovir .40 ng/mL in Active Arms of Study
Prevalence
or Mean
Univariable
OR (95% CI) P
Multivariable
AOR (95% CI) P
HIV-negative partner, enrollment characteristics
Age: 10-year increments 34 1.5 (1.1 to 1.9) 0.008 1.3 (1.0 to 1.8) 0.04
Male 64% 1.1 (0.7 to 1.7) 0.84 1.2 (0.7 to 2.0) 0.44
Years of education $6 versus ,6 72% 0.6 (0.4 to 1.1) 0.09 ——
HIV-positive partner, enrollment characteristics
CD4 count
,350 cells/mm3 20% 1.1 (0.6 to 2.2) 0.71
350–500 cells/mm3 30% 0.7 (0.4 to 1.2) 0.22 ——
.500 cells/mm3 50% Reference
HIV-negative partner, time-varying characteristics
(in the past quarter)
Primary income from farming 45% 1.8 (1.2 to 2.6) 0.004 1.7 (1.2 to 2.6) 0.008
Sexual behavior in the previous month
No sex 10% 0.5 (0.3 to 0.8) 0.009 0.5 (0.3 to 0.9) 0.022
Primary partner only, ,100% condom use 15% Reference Reference
Primary partner only, 100% condom use 66% 0.7 (0.5 to 1.1) 0.16 0.7 (0.5 to 1.1) 0.17
Other partner only 3% 0.5 (0.2 to 1.1) 0.08 0.6 (0.2 to 1.5) 0.26
Primary and other partner 6% 0.7 (0.4 to 1.6) 0.44 0.8 (0.4 to 1.7) 0.50
Disclosure of partner’s HIV status to anyone 53% 0.8 (0.5 to 1.2) 0.23 ——
Each add 6 months on PrEP — 0.84 (0.77 to 0.92) ,0.001 0.83 (0.76 to 0.92) ,0.001
HIV-positive partner, time-varying characteristics
(in the past quarter)
CD4 count
,200 cells/mm3 23% 1.2 (0.8 to 1.8) 0.47
200–349 cells/mm3 30% 0.8 (0.6 to 1.2) 0.31 ——
.350 cells/mm3 47% Reference
On ART 6% 0.7 (0.5 to 1.03) 0.07 ——
Partnership, enrollment characteristics
Not living together 3% 0.4 (0.3 to 0.8) 0.009 0.5 (0.2 to 1.4) 0.18
No children with partner 78% 1.0 (0.6 to 1.6) 0.84 ——
Polygamous marriage 18% 1.5 (0.8 to 2.7) 0.17 ——
Bold values indicate P , 0.05 (Wald).
ART, antiretroviral therapy.
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trations were associated with older age and shorter time on
study; plasma tenofovir concentrations #40 ng/mL occurred
more commonly during study intervals when participants
reported no sex with their HIV-infected partner, suggesting
that participants’ adherence to PrEP reﬂected their exposure
and perceived risk.
A modeling study in MSM combined data on intracel-
lular drug levels (concentration of tenofovir diphosphate,
TFV-DP, in peripheral blood mononuclear cells) from a study
with directly observed dosing of FTC/TDF to intracellular
TFV-DP concentrations associated with HIV protection from
a randomized clinical trial of PrEP. HIV transmission risk
reduction for MSM was estimated to be 76% for 2 doses per
week, 96% for 4 doses per week, and 99% for 7 doses per
week.
18 Our estimated efﬁcacy for concentrations .40 and
.10 ng/mL are comparably high, although we did not
observe a trend with drug concentration, largely because risk
reduction associated with any detectable tenofovir was very
high in our context of .80% controls with detectable drug.
Results from drug concentrations studies in PrEP trials con-
sistently ﬁnd very high levels of protection from HIV acqui-
sition associated with the presence of drug, supporting high
biologic efﬁcacy of these drugs to prevent HIV.
Adherence behavior was largely consistent over time
within individuals in our study: early nonadherers who were
not using PrEP after 1 month continued as nonusers, and
those who had high tenofovir concentrations at month 1
continued to be adherent to PrEP. Similar patterns of
persistent adherers and early nonadherers have been observed
for daily medication in other prevention ﬁelds.
19,20 For imple-
mentation, our results might imply that persons who decide to
initiate PrEP for HIV prevention will likely return for their
PrEP drugs and use consistently (with counseling and support),
whereas those not currently interested in PrEP may be unlikely
to initiate or return for reﬁlls. These patterns of consistent use
support the potential for cost effectiveness of targeted PrEP to
those who are motivated to use PrEP.
21–24 The high consistent
adherence may be due in part to the context of a mutually
disclosed serodiscordant relationship in the Partners PrEP
Study, where partner support and known risk of HIV infection
facilitate consistent adherence to a daily pill regimen.
25,26 The
success of a daily prevention medication among HIV serodis-
cordant couples motivates exploring where support for adher-
ence behaviors from a friend or family member as an adherence
“buddy” may have a similar effect for persons receiving PrEP
outside an explicit couples setting.
High adherence, deﬁned by plasma tenofovir concen-
trations, was related to older age, farming, and shorter length
of time on study. Older age and shorter duration of use
are similarly predictors of adherence in cardiovascular pre-
vention
27–31; participants whose primary income was from
FIGURE 2. Pill count coverage and
quantiﬁed tenofovir levels in plasma.
Pill count coverage combines pill
count and dispensing data to esti-
mate the percentage of days since
the previous visit that pills were
taken.
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from home that could disrupt daily pill taking. Notably, per-
sons reporting no sex with their HIV-infected partner in the
previous month had decreased adherence. A previous analysis
from this same clinical trial found a similar association of
lower adherence to PrEP during times with no sex, with
adherence measured using electronic pill bottle openings,
and unannounced home visit pills count.
7 Together, these
results suggest that periods of lower adherence to PrEP cor-
responded to periods of no sexual risk, a rational response to
reduced risk of HIV exposure, raising the possibility that in
implementation, PrEP users may pause use when not sexually
active. Future work on adherence counseling, together with
PK studies to inform drug timing, will be needed to determine
whether to urge continued PrEP use even while not sexually
active or to support discontinuation but develop approaches
that ensure PrEP is restarted before re-initiation of sex.
Importantly, given the lack of efﬁcacy of FTC/TDF
and/or oral TDF in the FemPrEP and VOICE trials,
5,6 high
efﬁcacy was observed with oral TDF in women in the Partners
PrEP Study, which was comparable with FTC/TDF and did not
differ from that of men. The lower protective effect for HIV
associated with lower plasma tenofovir concentrations in
women assigned to the TDF arm could be a chance imbalance.
However, it could also suggest that protection against HIV
acquisition for women using an oral TDF-only regimen is more
signiﬁcantly impacted than with oral FTC/TDF PrEP, if doses
are missed. A PK study of a single dose of FTC/TDF in
women showed similar plasma concentrations of tenofovir
and FTC but 10-fold lower concentrations of tenofovir than
FTC in cervicovaginal ﬂuids and vaginal tissues at all time
points.
13 Our ﬁnding, in which efﬁcacy is strongly associated
with tenofovir .40 ng/mL but not with tenofovir .10 ng/mL,
suggests that HIV protection in women with daily oral TDF
may be less forgiving of missed dosing than FTC/TDF because
plasma concentrations #40 ng/mL likely indicate a last dose
more than 2 days ago.
13
Importantly for clinical trials, participant-dependent
measures of adherence, for example, self-reported and pill
counts based on returned medication, can be substantially
higher than demonstrated by biologic adherence measures.
5,6,32
Speciﬁcally, in VOICE, adherence was 84%–88% by pill
counts but 29%–30% by detectable tenofovir ($0.31 ng/mL);
in FEMPrEP, 88% by pill counts and 35% by detectable teno-
fovir ($10 ng/mL); and in iPrEx, 89% by pill count and 51%
by detectable tenofovir ($10 ng/mL).
1,5,6 Partners PrEP had
15% of visits with high adherence by pill count, yet undetect-
able tenofovir. We also found, as previously reported from an
HIV prevention trial with twice daily dosing,
32 that .100%
adherence by pill count may indicate lower adherence or
dumped study drug, as indicated by lower detectable drug con-
centrations. Understanding the reasons why pill counts can be
inﬂuenced by participant’s desire to seem adherent—thus
over-estimating adherence—potentially include social desirabil-
ity and/or fear of consequences in clinical trial participation;
eliciting motivations for these behaviors remains a critical
ﬁrst step in developing and implementing effective interven-
tions to enhance adherence and accuracy of self-reported
adherence in clinical trials. Importantly, effectiveness trials of
self-administered medication still rely on monitoring adherence
using participant-dependent measures.
33 The over-estimation of
near-perfect adherence by pill count may indicate that interim
evaluations of objective adherence measures, such as drug
levels, are important adjunct measures to monitor whether
there is sufﬁcient uptake of the study drug to evaluate efﬁcacy.
Objective behavioral measures, such as electronic monitoring,
in a subset of participants may be needed to study patterns of
adherence.
A limitation of plasma concentrations as a biomarker of
adherence is that extrapolation to degree of adherence over time
relies on the assumption that a single point in time is a reliable
i n d i c a t o ro fb e h a v i o ro v e rt h ep r e c e d i n gt i m ei n t e r v a l —in par-
ticular, “white-coat” dosing would result in high plasma levels
that could, for example, explain tenofovir concentrations
observed in seroconverters. In addition, concentrations in
plasma do not measure cellular uptake and phosphorylation to
the active metabolites, thus our data cannot be used to model
risk reduction for different dosing intensities.
In summary, tenofovir concentrations in plasma, which
were consistent with daily dosing, were highly predictive of
protection from HIV. In a population at known risk for
infection from an HIV-infected partner who was aware of
their study participation and could provide adherence support,
participants had consistent patterns of adherence over multiple
time points, with the majority able to achieve and sustain PrEP
adherence. These data strongly support the use of PrEP for the
prevention of HIV infection in heterosexual men and women.
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(Kabwohe Clinical Research Center): Elioda Tumwesigye; Jinja, Uganda
(Makerere University, University of Washington): Patrick Ndase, Elly Katabira;
Kampala, Uganda (Makerere University): Elly Katabira, Allan Ronald; Kisumu,
Kenya (Kenya Medical Research Institute, University of California San
Francisco): Elizabeth Bukusi, Craig R. Cohen; Mbale, Uganda (The AIDS
Support Organization, CDC-Uganda): Jonathan Wangisi, James D. Campbell,
Jordan W. Tappero; Nairobi, Kenya (University of Nairobi, University of
Washington): James Kiarie, Carey Farquhar, Grace John-Stewart; Thika, Kenya
(University of Nairobi, University of Washington): Nelly R. Mugo; Tororo,
Uganda (CDC-Uganda, The AIDS Support Organization): James D. Campbell,
Jordan W. Tappero, Jonathan Wangisi. Data management was provided by DF/
Net Research, Inc. (Seattle, WA) and site laboratory oversight was provided by
Contract Laboratory Services (CLS) of the Wits Health Consortium (University
of the Witwatersrand, Johannesburg, South Africa).
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